MX2023007007A - Composiciones para llegar al receptor en productos finales de glicacion avanzada (rage) en un padecimiento inflamatorio cronico. - Google Patents
Composiciones para llegar al receptor en productos finales de glicacion avanzada (rage) en un padecimiento inflamatorio cronico.Info
- Publication number
- MX2023007007A MX2023007007A MX2023007007A MX2023007007A MX2023007007A MX 2023007007 A MX2023007007 A MX 2023007007A MX 2023007007 A MX2023007007 A MX 2023007007A MX 2023007007 A MX2023007007 A MX 2023007007A MX 2023007007 A MX2023007007 A MX 2023007007A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory condition
- rage
- products
- compositions
- advanced glycation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 title abstract 3
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 title abstract 3
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 230000004968 inflammatory condition Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 abstract 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 abstract 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
Abstract
La invención describe composiciones y métodos que comprenden bisdemetoxicurcumina enriquecida (BDMC) presente en no menos del 20% p/p para su uso en la inhibición de la expresión del receptor para productos finales de glicación avanzada (RAGE) en un sujeto con afección inflamatoria crónica. La composición comprende además palmitato de B-amiriha (BAR). La invención también incluye divulgar el uso de la composición anterior en el tratamiento de una condición inflamatoria crónica en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126920P | 2020-12-17 | 2020-12-17 | |
PCT/US2021/063676 WO2022133011A1 (en) | 2020-12-17 | 2021-12-16 | Compositions for targeting receptor for advanced glycation end-products (rage) in a chronic inflammatory condition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007007A true MX2023007007A (es) | 2023-08-02 |
Family
ID=82021900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007007A MX2023007007A (es) | 2020-12-17 | 2021-12-16 | Composiciones para llegar al receptor en productos finales de glicacion avanzada (rage) en un padecimiento inflamatorio cronico. |
MX2023007009A MX2023007009A (es) | 2020-12-17 | 2021-12-16 | Composiciones para el tratamiento eficaz de la artritis reumatoide mediada por sinoviocitos similares a fibroblastos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007009A MX2023007009A (es) | 2020-12-17 | 2021-12-16 | Composiciones para el tratamiento eficaz de la artritis reumatoide mediada por sinoviocitos similares a fibroblastos. |
Country Status (8)
Country | Link |
---|---|
US (4) | US20220193006A1 (es) |
EP (3) | EP4262768A1 (es) |
JP (3) | JP2023554642A (es) |
KR (2) | KR20230119160A (es) |
CN (2) | CN116801733A (es) |
CA (3) | CA3200074A1 (es) |
MX (2) | MX2023007007A (es) |
WO (4) | WO2022133022A1 (es) |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU768189B2 (en) * | 1999-06-15 | 2003-12-04 | Nutri-Logics, Inc. | Nutrient formulations for disease reduction, and related treatment and component screening methods |
US7728043B2 (en) * | 1999-10-22 | 2010-06-01 | Kim Darrick S H L | Methods for treatment of beta-amyloid protein-induced ocular disease |
WO2002066491A1 (en) * | 2001-02-15 | 2002-08-29 | Sabinsa Corporation | Water soluble boswellic acids, their preparation and use for treating imflammatory conditions |
US9492402B2 (en) * | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
KR101483715B1 (ko) * | 2008-01-31 | 2015-01-19 | 큐어백 게엠바하 | 면역증강제/애주번트인 화학식(NuGlXmGnNv)a를 포함하는 핵산 및 이의 유도체 |
US8858995B2 (en) * | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
WO2009143391A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
EP2303328B1 (en) * | 2008-05-29 | 2017-12-20 | Universite Libre De Bruxelles | Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy |
JP2012510466A (ja) * | 2008-12-01 | 2012-05-10 | ライラ ファーマシューティカルズ ピーブイティ.エルティディ. | 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤 |
CA2732915C (en) * | 2010-03-02 | 2017-09-05 | Muhammed Majeed | Composition comprising boswellic acid for downregulating/inhibiting pro-inflammatory markers |
US9889105B2 (en) * | 2010-11-02 | 2018-02-13 | U.S. Department Of Veterans Affairs | In vivo method for treating, inhibiting, and/or prophylaxis of cancer, such as pancreatic cancer |
US20130296440A1 (en) * | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
CN106232183A (zh) * | 2014-04-18 | 2016-12-14 | 奥米尼埃克蒂夫健康科技有限公司 | 姜黄素组合物及其用途 |
US10085951B2 (en) * | 2014-12-11 | 2018-10-02 | Designs For Health, Inc. | Curcuminoid formulations and related methods of treatment |
US9782364B1 (en) | 2015-11-02 | 2017-10-10 | Franco Cavaleri | Curcumin-based compositions and methods of use thereof |
US10085963B2 (en) * | 2015-11-10 | 2018-10-02 | Sami Labs Limited | Process and compositions for achieving mammalian energy balance |
WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
MX2017016719A (es) * | 2017-12-19 | 2020-01-20 | Alepharma Soc Anonima Promotora De Inversion De Capital Variable | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
BR112020012949A2 (pt) * | 2017-12-27 | 2021-01-05 | Sami Labs Limited | Composições para o gerenciamento de hiperglicemia e afecções relacionadas |
US20220211681A1 (en) * | 2019-05-17 | 2022-07-07 | Trustees Of Tufts College | Compositions and methods for preventing inflammatory conditions |
CN114728876A (zh) * | 2019-10-15 | 2022-07-08 | 萨米-萨宾莎集团有限公司 | 姜黄素类组合物及其处理肺纤维化的治疗潜力 |
-
2021
- 2021-12-16 MX MX2023007007A patent/MX2023007007A/es unknown
- 2021-12-16 MX MX2023007009A patent/MX2023007009A/es unknown
- 2021-12-16 WO PCT/US2021/063691 patent/WO2022133022A1/en active Application Filing
- 2021-12-16 EP EP21907778.1A patent/EP4262768A1/en active Pending
- 2021-12-16 US US17/552,535 patent/US20220193006A1/en active Pending
- 2021-12-16 WO PCT/US2021/063676 patent/WO2022133011A1/en active Application Filing
- 2021-12-16 KR KR1020237022300A patent/KR20230119160A/ko unknown
- 2021-12-16 JP JP2023537123A patent/JP2023554642A/ja active Pending
- 2021-12-16 CN CN202180085189.7A patent/CN116801733A/zh active Pending
- 2021-12-16 JP JP2023537120A patent/JP2023554640A/ja active Pending
- 2021-12-16 CN CN202180085384.XA patent/CN116847833A/zh active Pending
- 2021-12-16 CA CA3200074A patent/CA3200074A1/en active Pending
- 2021-12-16 EP EP21907769.0A patent/EP4262429A1/en active Pending
- 2021-12-16 CA CA3200069A patent/CA3200069A1/en active Pending
- 2021-12-16 CA CA3200072A patent/CA3200072A1/en active Pending
- 2021-12-16 WO PCT/US2021/063689 patent/WO2022133020A1/en active Application Filing
- 2021-12-16 JP JP2023537122A patent/JP2023554641A/ja active Pending
- 2021-12-16 US US17/552,491 patent/US11957728B2/en active Active
- 2021-12-16 US US18/265,903 patent/US20230381117A1/en active Pending
- 2021-12-16 EP EP21907776.5A patent/EP4262982A1/en active Pending
- 2021-12-16 KR KR1020237023350A patent/KR20230121791A/ko unknown
- 2021-12-17 US US17/644,990 patent/US20220193178A1/en active Pending
- 2021-12-17 WO PCT/US2021/063936 patent/WO2022133158A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA3200069A1 (en) | 2022-06-23 |
JP2023554641A (ja) | 2023-12-28 |
WO2022133020A1 (en) | 2022-06-23 |
US11957728B2 (en) | 2024-04-16 |
WO2022133022A1 (en) | 2022-06-23 |
US20230381117A1 (en) | 2023-11-30 |
CA3200072A1 (en) | 2022-06-23 |
CN116801733A (zh) | 2023-09-22 |
MX2023007009A (es) | 2023-08-02 |
JP2023554640A (ja) | 2023-12-28 |
US20220193005A1 (en) | 2022-06-23 |
EP4262982A1 (en) | 2023-10-25 |
EP4262768A1 (en) | 2023-10-25 |
CN116847833A (zh) | 2023-10-03 |
US20220193178A1 (en) | 2022-06-23 |
KR20230121791A (ko) | 2023-08-21 |
KR20230119160A (ko) | 2023-08-16 |
WO2022133011A1 (en) | 2022-06-23 |
JP2023554642A (ja) | 2023-12-28 |
EP4262429A1 (en) | 2023-10-25 |
US20220193006A1 (en) | 2022-06-23 |
CA3200074A1 (en) | 2022-06-23 |
WO2022133158A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006908A (es) | Composiciones orales humedas. | |
MX2009010067A (es) | Analogos de imidazolopirimidina y su uso como inhibidores de mtor y cinasa pi3. | |
NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
MX2010005210A (es) | Formulacion de aceite de oliva para alivio del dolor. | |
ATE544444T1 (de) | Zusammensetzungen für die nasale abgabe | |
MX2009009624A (es) | Droxidopa y composicion farmaceutica de la misma para el tratamiento de la fibromialgia. | |
BR112014012689A2 (pt) | montagem e método de uso de um cateter e método para administração de uma composição antimicrobiana | |
YU64701A (sh) | Jedinjenja upotrebljiva kao anti-inflamatorna sredstva | |
MX2021005365A (es) | Preparaciones y composiciones de oligosacaridos. | |
AR066916A1 (es) | Anticuerpos conra c3b y metodos para la prevenc ion y el tratamiento de trastornos asociados con el complemento. composicion farmaceutica. | |
WO2006128032A3 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflammation | |
AR078553A1 (es) | Composicion de bajo contenido de eter y aparato de administracion | |
BRPI0408373A (pt) | composições para tratamento de pele que aumentam e reparam a função de barreira da pele | |
CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
TR201818761T4 (tr) | 4-amino-5-floro-3-[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]-1h-kinolin-2-on laktat monohidrat içeren farmasötik bileşimler. | |
EP2547209A4 (en) | FUNGICIDAL COMPOSITIONS COMPRISING A PHOSPHATE SOLUBILIZING MICROORGANISM AND A FUNGICIDE ACTIVE COMPOUND | |
CO2020010193A2 (es) | Una composición farmacéutica para la anemia | |
HK1127556A1 (en) | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases | |
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
WO2021067996A3 (en) | Oral care compositions with anticaries activity | |
BR112015029468A8 (pt) | sistemas de dosagem oralmente administráveis, método para suplementar a nutrição de ferro em um indivíduo humano e métodos para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido | |
MX2021009535A (es) | Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. | |
MX2023007007A (es) | Composiciones para llegar al receptor en productos finales de glicacion avanzada (rage) en un padecimiento inflamatorio cronico. | |
MY186286A (en) | A pharmaceutical composition for improving or preventing progression of chronic kidney disease | |
MX2013014518A (es) | Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio. |